Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 30, 2018August 30, 2018

Amgen Seeks Expanded Approval of Kyprolis to Once-weekly Regimen for Relapsed Myeloma

News

Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for multiple myeloma patients with hard-to-treat disease or ... Read more

August 27, 2018August 27, 2018

FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma

News

The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and low-dose dexamethasone as a treatment for patients with relapsed or treatment-resistant multiple ... Read more

August 6, 2018

Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma

News

The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing the investigational therapy. Orphan drug designation aims ... Read more

August 3, 2018

CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients

News

Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell transplant, has been recommended by ... Read more

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

June 29, 2018

Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show

News

Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment, data from the Phase 2 ELOQUENT-3 trial ... Read more

June 25, 2018

Mutations in Noncoding Regions of Human Genome Also Cause Cancer, Study Shows

News

While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our genome, researchers found. University ... Read more

June 22, 2018

Advanced Myeloma Patients Responding to Selinexor Plus Standard Therapies in Trial, Data Show

News

Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm Therapeutics announced. This data — from the ... Read more

May 14, 2018

FDA Names Cancer Vaccine Galinpepimut-S Orphan Drug as Possible Multiple Myeloma Treatment

News

The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of multiple myeloma, Sellas Life Sciences ... Read more

March 21, 2018March 21, 2018

Medicinal Cannabis Safe and Effective for Pain, Chemo Side Effects, Journal Says

News

The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of research data shows. In ... Read more